Metastatic breast cancer is diagnosed through a combination of imaging scans, a biopsy of the suspected metastatic site, and blood work. The process typically begins when new symptoms appear, routine follow-up scans flag something abnormal, or, in some cases, when a person is first diagnosed with breast cancer that has already spread. From the first suspicious finding to a confirmed diagnosis, the full workup can take anywhere from a few weeks to several months depending on wait times for imaging and biopsy appointments.
How the Workup Typically Starts
The diagnostic process follows a fairly predictable sequence. It begins with a physical exam and a detailed history of your symptoms, which might include new bone pain, persistent cough, unexplained weight loss, or neurological changes like headaches or vision problems. Your oncologist uses this information to decide which imaging tests to order first and which parts of the body to focus on.
Breast cancer most commonly spreads to the bones, lungs, liver, and brain. So the initial imaging workup is designed to check those areas systematically. After imaging identifies suspicious spots, a biopsy is performed to confirm whether the tissue is actually cancerous and, critically, to test its receptor status. Blood tests run alongside imaging help round out the picture but are not enough on their own to confirm a diagnosis.
Imaging Scans Used to Find Spread
Several types of scans are used, and each has strengths for different parts of the body.
PET/CT scans are one of the most powerful tools for detecting distant metastases. A PET/CT combines a metabolic scan (which lights up areas with high cellular activity) with a detailed CT image. In a study published in The Oncologist comparing PET/CT to conventional imaging (chest X-ray, bone scan, and CT of the chest, abdomen, and pelvis), PET/CT had a sensitivity of 97.4% and specificity of 91.2%, compared to 85.9% sensitivity and 67.3% specificity for conventional methods. In practical terms, PET/CT catches more metastases and produces fewer false alarms.
CT scans of the chest, abdomen, and pelvis remain a standard part of the workup, especially for spotting lung and liver metastases. Radiologists look for specific patterns: pulmonary nodules, soft tissue along the lining of the lungs, or liver lesions with irregular enhancement. These scans are typically done with contrast dye to improve visibility.
Bone scans (bone scintigraphy) are commonly ordered because bone is the single most frequent site of breast cancer metastasis. A bone scan picks up skeletal metastases with about 93% sensitivity, but its specificity is lower at 86%, meaning it can flag areas that turn out to be benign, like arthritis or old fractures. MRI outperforms bone scans significantly here, with both sensitivity and specificity around 99%. MRI can clearly distinguish between cancerous and non-cancerous bone abnormalities, so it’s often used as a follow-up when bone scan results are ambiguous.
Brain MRI is not routinely ordered for all patients with metastatic breast cancer. Current guidelines recommend brain imaging only when neurological symptoms are present, such as new headaches, seizures, or cognitive changes. However, certain subtypes carry higher risk: triple-negative and HER2-positive breast cancers have the highest rates of brain metastases. A phase II trial is currently investigating whether routine brain MRI surveillance in asymptomatic patients with these subtypes could catch metastases earlier, but this is not yet standard practice.
Why a Biopsy of the Metastatic Site Matters
Imaging can show that something suspicious is there, but it cannot confirm cancer or reveal its biology. That requires a tissue biopsy of the metastatic site itself. Both NCCN and European consensus guidelines recommend biopsying the first site of recurrence or metastasis whenever it is safely accessible.
The biopsy serves two purposes. First, it confirms that the lesion is actually breast cancer and not a different type of cancer or a benign process. Second, and perhaps more important for treatment planning, it tests the tumor’s receptor status: estrogen receptor (ER), progesterone receptor (PR), and HER2.
Here’s why that second purpose is so critical: the receptor profile of a metastatic tumor frequently differs from the original breast cancer. In one study of 50 patients, hormone receptor conversion between the primary tumor and the metastasis occurred in 60% of cases. Estrogen receptor status changed in 26% of patients, most often flipping from positive to negative. Progesterone receptor changes were even more common, occurring in 52% of cases. HER2 status, by contrast, rarely changed, shifting in only 2% of cases.
These conversions directly affect treatment decisions. A tumor that was hormone receptor-positive at initial diagnosis but has become negative at the metastatic site would no longer respond to hormone-blocking therapies. Without a fresh biopsy, treatment would be based on outdated information.
The Role of Blood Tests
Blood tests are part of the diagnostic workup but play a supporting role rather than a definitive one. The two most commonly used tumor markers in breast cancer are CA 15-3 and CEA.
CA 15-3 levels up to 30 U/mL are considered normal. Elevated levels in someone with a history of breast cancer can signal disease progression or recurrence, and in patients with metastatic disease, higher CA 15-3 levels are associated with worse outcomes. However, tumor markers alone cannot diagnose metastatic breast cancer. They can be elevated for other reasons, and some patients with confirmed metastases have normal marker levels. Their main value is in tracking disease over time: a rising trend may prompt imaging sooner than scheduled.
Liquid biopsies, which analyze circulating tumor DNA shed by cancer cells into the bloodstream, represent a newer approach. These tests can provide prognostic information and help monitor disease burden. But as of now, liquid biopsy has not replaced traditional tissue biopsy for diagnosing metastatic breast cancer. Prospective trials demonstrating that liquid biopsy results should change clinical decision-making are still limited.
What the Timeline Looks Like
The time between a first suspicious finding and a confirmed metastatic diagnosis varies widely. Imaging appointments may come within a week in urgent situations or take several weeks depending on your location and the type of scan. Needle biopsies typically take three to four weeks to schedule, though delays beyond that are not uncommon. Once a biopsy is performed, initial pathology results, including receptor subtype classification, should be reported within about seven days.
Guidelines suggest that the entire path from an initial abnormal imaging result to a confirmed diagnosis should take no longer than six weeks, and a first consultation with a specialist should happen within two weeks of referral. In practice, these timelines stretch in many healthcare systems, which can be a source of significant anxiety. If you feel your workup is stalling, asking your care team about expedited scheduling or referral to a cancer center with shorter wait times is reasonable.
De Novo Versus Recurrent Metastatic Disease
Not everyone with metastatic breast cancer had an earlier-stage diagnosis first. About 6% to 10% of breast cancers are metastatic at the time of first diagnosis, known as de novo stage IV disease. The diagnostic workup is essentially the same: full-body imaging followed by biopsy of a metastatic site and receptor testing. The difference is that everything happens at once rather than being triggered by a recurrence years later, and the primary breast tumor is biopsied alongside the metastatic lesion to compare the biology of both.
For people previously treated for early-stage breast cancer, metastatic disease is most often suspected when new symptoms develop or when surveillance bloodwork shows rising tumor markers. The workup then follows the same imaging-then-biopsy sequence, with particular attention to confirming that the receptor status hasn’t shifted since the original diagnosis.